Nagorsen Dirk, Thiel Eckhard
Charité Universitätsmedizin Berlin, Department of Hematology and Oncology, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany.
Curr Opin Investig Drugs. 2007 Dec;8(12):996-1001.
The application of highly specific mAbs with minimal side effects in cancer therapy was, for a long time, a major goal for many clinical oncologists. Since their arrival in the clinical setting, mAbs have come to represent a standard therapy for some tumors, and have proven to be an important extension to the treatment of a broad spectrum of malignancies. The future development of mAbs for targeting alone (ie, for labeling of tumors) is insufficient for obtaining a suitable clinical response, and adequate clinical success can only be achieved by arming mAbs and targeting them to functionally significant tumor antigens such as tumor growth-related receptors. This review provides an overview of the functional characteristics of mAbs, together with some important examples of their clinical application. While mAbs may not be the 'magic bullets' that many researchers had hoped for, they are nevertheless becoming an indispensable pillar of tumor therapy.
长期以来，在癌症治疗中应用副作用极小的高特异性单克隆抗体是许多临床肿瘤学家的主要目标。自从单克隆抗体进入临床应用以来，它们已成为某些肿瘤的标准疗法，并已被证明是广泛恶性肿瘤治疗的重要扩展。仅用于靶向（即标记肿瘤）的单克隆抗体的未来发展不足以获得合适的临床反应，只有通过武装单克隆抗体并将它们靶向功能上重要的肿瘤抗原（如肿瘤生长相关受体）才能取得足够的临床成功。本综述概述了单克隆抗体的功能特性以及它们临床应用的一些重要实例。虽然单克隆抗体可能不是许多研究人员所期望的“神奇子弹”，但它们仍然正在成为肿瘤治疗中不可或缺的支柱。
